Insight

Hung Trinh Highlighted a Study on VNX-101

Hung Trinh/LinkedIn

Aug 17, 2025, 12:42

Hung Trinh Highlighted a Study on VNX-101

Hung Trinh, Senior VP of Operations at Seneca Therapeutics, Inc., shared on LinkedIn about a recent paper by Mark A Currier et al. published on Molecular Therapy:

“Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager

We previously described the use of recombinant adeno-associated virus (AAV) gene therapy to achieve off-the-shelf, long-term in vivo T cell engagement for CD19+ B cell malignancies following a single dose by expressing a transgene encoding a bispecific diabody termed GP101. Here we describe the selection and development of a clinical lead construct, VNX-101, with enhanced safety and efficacy features.

A single dose of the virus was effective at eliminating B cell malignancies in humanized mouse xenograft models. We observed a linear dose-dependent increase in serum concentrations of GP101 over a three-log range in mice, with transduction and serum levels lower in females than males.

There were no concerning safety signals and the No Observed Adverse Event Level was determined to be >2.7E13 vg/kg. We also conducted a 12-week study to evaluate the pharmacokinetics, biodistribution, in-life safety, gross pathology, and histopathology in hamadryas baboon monkeys. VNX-101 treatment was well tolerated with no significant changes in body weight or clinical signs reported.

Collectively, these preclinical data support the efficacy and safety of VNX-101 as a potential AAV-based treatment for cancer. A phase 1/2 clinical trial of VNX-101 for relapsed or refractory B cell malignancies is under way.”

Title: Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager

Authors: Mark A. Currier, Allen Reha, Brian Hutzen, Pin-Yi Wang, Chun-Yu Chen, Andrea M. Glaspell, Siddhi Nath Paudel, Akila S. Venkataramany, Debashree Das, Danielle Hanlon, Allan Kaspar, Samit Varma, Brian Kaspar, Pablo Morales, Peter Ralph, Tonny Johnson, Tania L. Weiss, Timothy P. Cripe

Read the Full Article.

More posts featuring Hung Trinh.

Akila S. Venkataramany Allan Kaspar Allen Reha Andrea M. Glaspell Brian Hutzen Brian Kaspar Chun-Yu Chen Danielle Hanlon Debashree Das Hung Trinh Mark A. Currier Pablo Morales Peter Ralph Pin-Yi Wang Samit Varma Siddhi Nath Paudel Tania L. Weiss Timothy P. Cripe Tonny Johnson

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth

New FDA PreCheck Program to Boost U.S. Drug Manufacturing

Vinay Prasad Rejoins FDA Days After Exit